TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-W

Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We

Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weig

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform a

Analysts downgraded Honeywell Aerospace, Intel, Bright Horizons, Alnylam and Maplebear, cutting rati

Raymond James analyst Martin Auster downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Strong

Investigation follows the July 30, 2026 disclosure regarding Alnylam Pharmaceuticals, Inc.; investor

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lo

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript

Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The

Alnylam Pharmaceuticals NASDAQ: ALNY reported third-quarter 2026 global net product revenue of appro

Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 r

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $16.26 per share, beating the Zac

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter financial results on Thursday. The tran

Alnylam Pharmaceuticals (NASDAQ:ALNY) affirms FY2026 sales outlook from $5.275 billion-$5.725 billio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

Get a deeper insight into the potential performance of Alnylam (ALNY) for the quarter ended Septembe

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntingto

Alnylam Pharmaceuticals NASDAQ: ALNY outlined early clinical data for brezosiran, an investigational

Alnylam Pharmaceuticals, Inc.'s shares remain under pressure. Meanwhile, on October 23, Alnylam repo

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, to

- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64%

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat

Alnylam's stock has plunged more than 40% this year, but the company's financials look great. Invest

Curated Wealth Partners LLC decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:

First Citizens Bank and Trust Co. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: AL

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, an

Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowe

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 12.41% o

Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis exp

Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Onconetix (NASDAQ: ONCO - Get Free Repo

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform a

The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQ

LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national

Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accen

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.0% on

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:AL

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:AL

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are gree